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Background and Objective: The United States FDA recently released a “boxed” warning that clopidogrel may be less effective in people who are 
unable to metabolize the drug because of low CYP2C19 activity. We sought to evaluate the predictive performance of platelet CYP2C19 and ABCB1 
genotyping.
Methods:  Data from 4 randomized trials and a 10-trial meta-analysis (Hulot et al) were analyzed to calculate sensitivity (Sn), specificity (Sp), 
positive (PPV) and negative predictive value (NPV), positive (LR+) and negative likelihood ratio (LR-), and area under the curve (AUC) c index for 
major adverse cardiovascular outcomes (MACE) and major bleeding associated with CYPC2C19 and ABCB1 loss-of-function genetic variants.
Results (Table): The PPV of CYP2C19 and ABCB1 for MACE ranges from 8% to 22%, the NPV ranges from 83% to 92%. The corresponding LR+ are 
<1.5 and LR- are >0.80, indicating small to tiny impact on MACE risk prediction. The c index ranges from 0.50 to 0.59, indicating little discriminating 
capacity. The predictive performance of these genetic variants is even less pronounced for bleeding (PPV 4% to 11%; NPV 91% to 98%; c index 0.54 
to 0.62).
Conclusion: Genotyping for CYP2C19 and ABCB1 alleles does not capture all of the variability in responses to clopidogrel. Given the weak to 
modest risk prediction for both ischemic and bleeding outcomes, our results support the ACC/AHA Clopidogrel Clinical Alert recommendation that 
“the evidence base is insufficient to recommend genetic testing at the present time.” 
Study Sn Sp PPV NPV LR+ LR- AUC
CYP2C19 for MACE
CURE 0.27 0.67 8% 89% 0.81 1.10 0.45
ACTIVE A 0.39 0.67 22% 83% 1.20 0.90 0.55
TRITON 0.36 0.74 12% 92% 1.36 0.87 0.57
PLATO 0.31 0.72 11% 91% 1.11 0.96 0.52
Hulot meta-analysis 0.33 0.72 10% 92% 1.17 0.93 0.54
ABCB1 for MACE
PLATO 0.27 0.73 10% 90% 1.00 1.00 0.50
TRITON 0.39 0.73 13% 92% 1.46 0.83 0.59
CYP2C19 for Major Bleeding
CURE 0.31 0.67 4% 96% 0.94 1.03 0.48
ACTIVE A 0.50 0.67 10% 95% 1.52 0.75 0.62
PLATO 0.57 0.49 11% 91% 1.12 0.88 0.54
ABCB1 for Major Bleeding
TRITON 0.37 0.72 4% 98% 1.32 0.88 0.57
